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Abstract 
 
Background: Diabetic nephropathy is a serious complication of diabetes mellitus and is 
associated with considerable morbidity and high mortality.   There is increasing evidence to 
suggest that dysregulation of the epigenome is involved in diabetic nephropathy. We 
assessed whether epigenetic modification of DNA methylation is associated with diabetic 
nephropathy in a case-control study of 192 Irish patients with type 1 diabetes mellitus 
(T1D). Cases had T1D and nephropathy whereas controls had T1D but no evidence of renal 
disease.   
Methods: We performed DNA methylation profiling in bisulphite converted DNA from cases 
and controls using the recently developed Illumina Infinium® HumanMethylation27 
BeadChip, that enables the direct investigation of 27,578 individual cytosines at CpG loci 
throughout the genome, which are focused on the promoter regions of 14,495 genes. 
Results: Singular Value Decomposition (SVD) analysis indicated that significant components 
of DNA methylation variation correlated with patient age, time to onset of diabetic 
nephropathy, and sex. Adjusting for confounding factors using multivariate Cox-regression 
analyses, and with a false discovery rate (FDR) of 0.05, we observed 19 CpG sites that 
demonstrated correlations with time to development of diabetic nephropathy.  Of note, this 
included one CpG site located 18 bp upstream of the transcription start site of UNC13B, a 
gene in which the first intronic SNP rs13293564 has recently been reported to be associated 
with diabetic nephropathy. 
Conclusion: This high throughput platform was able to successfully interrogate the 
methylation state of individual cytosines and identified 19 prospective CpG sites associated 
with risk of diabetic nephropathy. These differences in DNA methylation are worthy of 
further follow-up in replication studies using larger cohorts of diabetic patients with and 
without nephropathy.3 
 
Background 
   
Diabetic nephropathy is a serious microvascular complication of diabetes and has 
become the most common cause of end-stage renal disease (ESRD) in many national ESRD 
registries [1, 2]. Approximately one third of diabetic individuals will develop clinically 
apparent nephropathy characterised by persistent proteinuria, hypertension and eventual 
progressive decline in glomerular filtration rate [3, 4]. Whilst chronic hyperglycaemia is 
integral to the pathogenesis of diabetic nephropathy there is also strong evidence for a 
genetic susceptibility to this common complication of diabetes [5-7]. In genetically 
susceptible individuals, prolonged hyperglycaemia leads to chronic metabolic and 
haemodynamic changes [8, 9] whose effects, including those driven by transforming growth 
factor beta 1 (TGFβ1), promote structural abnormalities in the kidney such as glomerular 
basement membrane thickening, podocyte injury, and mesangial matrix expansion, with the 
later development of irreversible glomerular sclerosis and tubulointerstitial fibrosis [10].  
Genetic studies have found evidence for linkage to nephropathy at a number of 
chromosome loci including 2q, 3q22 and 19q [11, 12]. While no consistently replicated 
genetic associations have been identified, various candidate gene associations in diabetic 
nephropathy in type 1 diabetes (T1D) have been proposed, such as the SNP rs13293564 G/T 
substitution in intron 1 of UNC13B [13], and SOD1 SNPs [14].  An association with the 
ELMO1 gene and diabetic nephropathy was initially identified in patients with type 2 
diabetes mellitus [15] and this association has now also been reported for diabetic 
nephropathy in T1D [16]. A recent genome-wide association study identified FRMD3 and 
CARS gene variants as possible genetic susceptibility factors for T1D diabetic nephropathy 
[17]. 
Epigenetic mechanisms allow alteration of genome function without mutating the 
underlying sequence. They involve the interacting actions of DNA methylation (the addition 
of a methyl group to the 5th carbon position of cytosine), histone modifications and non-
coding RNAs [18]. A number of indirect lines of evidence point to the involvement of 
epigenetic changes in diabetic nephropathy. Murine models of disease progression 4 
 
displaying temporal variation in gene expression have indicated these supra-sequence 
devices may be involved in the pathogenesis [19]. Gene expression changes reflect dynamic 
alterations in gene transcription and also messenger RNA stability, which may be influenced 
by the epigenetic modification of the genome in response to chronic hyperglycaemic stress.  
Altered DNA methylation has been additionally implicated in vascular disease [20, 21]. 
Furthermore, characteristics observed in diabetic nephropathy such as 
hyperhomocysteinaemia, dyslipidaemia, inflammation and oxidative stress can promote 
aberrant DNA methylation [22-24].  
DNA methylation in mammalian species, except for pluripotent stem cells [25, 26], 
appears to occur almost exclusively at consecutive CpG dinucleotides, of which there are 
approximately 28 million located within the human genome [27]. The majority of cytosines 
in these dinucleotides remain methylated (~80% in Homo sapiens) [27], which contrasts 
with CpG islands (CGIs) in which cytosines are generally unmethylated. CGIs are regions that 
exceed genome average levels of CpG density and co-localise with 72% of gene promoters 
[28], notably in those of highly expressed genes.  
In order to assess possible changes in CpG methylation in a genome-wide manner 
we utilised the high throughput Illumina Infinium® Human Methylation27 BeadChip DNA 
methylation array to investigate association with nephropathy in a case-control study of 192 
T1D patients. These probes interrogate the methylation state of 27,578 individual CpGs 
located predominately in CGIs within proximal promoter regions, between 1.5 kb upstream 
and 1 kb downstream of the transcription start sites of 14,475 consensus coding sequence 
genes throughout the genome. Furthermore 110 miRNA promoters are targeted with 254 
CpG loci probes [29]. This platform enables the high-throughput array based investigation of 
individual CpGs at a magnitude higher level than the previous array based Golden-Gate 
assay [30].  
The development, as well as the progression, of diabetic nephropathy has been 
linked to the same inflammatory cell processes that are implicated in the progression of T1D 
itself, such as the activated T cells involved in the destruction of islet β cells [7]. Thus 
changes in the expression of cytokines and other inflammatory markers from distinct blood 5 
 
cell types make the investigation of methylation changes in DNA derived from blood a 
plausible option for examining epigenetic alterations in this disease. DNA methylation 
changes in peripheral blood have additionally been shown to indicate or be surrogate 
markers of active disease processes [31]. 
This study has investigated the possibility to identify DNA methylation biomarkers in 
peripheral blood cell-derived DNA that may be associated with the pathogenesis of T1D 
nephropathy. The study was designed to detect associations between the disease and 
differences in DNA methylation but not their functional relationship. Undertaken in a case 
control design, those with and without nephropathy were matched by age of onset and 
duration of diabetes.6 
 
Methods 
 
Participants  
 
Cases (n= 96) and controls (n = 96) were recruited from nephrology and diabetic 
clinics in Belfast and Dublin (Table 1). Genomic DNA was extracted from whole blood 
samples from cases and controls using a salting out method. All participants were white, 
with parents and grandparents born in Northern Ireland or the Republic of Ireland. Both 
cases and controls were diagnosed with T1D before the age of 31 years and required insulin 
from time of diagnosis. The definition of a case was based on development of persistent 
proteinuria (>0.5g protein/24h) at least 10 years after diagnosis of diabetes, hypertension 
(BP >135/85 mmHg or treatment with antihypertensive agents) and presence of diabetic 
retinopathy. In contrast, a control was defined as a patient with T1D duration of at least 15 
years with urinary albumin excretion in the normal range and not receiving antihypertensive 
treatment. Patients with microalbuminuria were excluded from both groups. Cases and 
controls were matched for confounders that may affect DNA methylation namely age, 
gender and duration of diabetes within five year windows. Study approval for each 
recruitment site was obtained from respective research ethics committees (Queens 
University Belfast and Mater Misericordiae Hospital, Dublin) and written informed consent 
was obtained from all participants.  
 
Bisulphite conversion of DNA 
 
Bisulphite conversion of 1ug genomic DNA was performed using the EZ-96 DNA 
Methylation-Gold™ Kit (©Zymo Research Corp., USA) in two 96 well plates according to the 
manufacturer’s instructions. Cases and controls were randomly located between the two 
plates. Effective bisulphite conversion was checked by successful PCR amplification with a 
pair of primers specific for converted DNA and unsuccessful amplification with a pair of 7 
 
primers for unconverted DNA, of 24 random samples across both plates (details available on 
request from authors).  
  
Illumina Infinium methylation assay 
 
DNA samples from cases and controls were interrogated utilising the Illumina 
Infinium® Human Methylation27 BeadChip. This platform detects the methylation status of 
27,578 CpG sites by sequencing-based genotyping of bisulphite treated DNA. The 
chromosomal distribution and other statistics relevant to these CpG sites are provided in 
Additional File 1: Supplementary Figure S1. This chemical modification of DNA converts only 
unmethylated cytosines to uracils, thereafter allowing for highly multiplexed genotyping 
with single site resolution. Bisulphite converted and unconverted (i.e. methylated) sites are 
simultaneously evaluated by hybridisation of DNA to site-specific probes attached to beads, 
one for unmethylated and the other for methylated sites, followed by allele specific base 
extension that includes a fluorescent label. Two different labels are used, and fluorescent 
signals are specific for either the T (unmethylated) or C (methylated) alleles. Methylation 
scores represented as β values are generated for each site using BeadStudio 3.2 software 
(© Illumina, Inc. 2003-2008) and are computed based on the ratio of methylated to 
methylated plus unmethylated signal outputs. Thus the β values range from 0 
(unmethylated) to 1 (fully methylated) on a continuous scale.  
This platform for quantitative methylation, essentially an adaptation of the highly 
successful Illumina Infinium I Whole Genome Genotype SNP genotyping assay used 
extensively for GWAS [32, 33], is extremely accurate and powerful.  Reproducibility 
estimates are extremely high with an average r
2 correlation for β-values of 0.992 for 24 
technical replicates [29]. Due to the high density of probes up to 12 separate samples can 
be assayed on a single BeadChip, thus allowing for high-throughput processing. 
The Illumina Infinium methylation assay was performed according to the 
manufacturer’s instructions, and this along with the technical validation of the assay is 
detailed in Bibikova et al. [29].  Bisulphite-converted DNA was denatured, amplified, 8 
 
fragmented and subsequently hybridised, with use of a specific hybridisation buffer, to the 
chip arrays (Sentrix positions A-L). Cases and controls were arranged to randomly 
approximate a 50:50 proportion on each chip. Primer extension was performed, then 
staining and coating, followed by imaging with the Illumina BeadArray reader. Internal 
quality controls included assessment of staining, hybridisation, target removal, extension, 
bisulphite conversion efficiency, dye specificity and additionally negative controls.  
 
Statistical analysis 
 
  Initial array results were visualised using Illumina® BeadStudio 3.2 (© Illumina Inc 
2003-2008). All computations and statistical analyses were performed using the R package 
(R 2.8.1) (http://www.r-project.org) [34] and Bioconductor [35].  
 
Quality control and data normalisation 
 
Quality control and normalisation of methylation data was undertaken using the 
analysis pipeline reported elsewhere [31]. Briefly, samples were monitored for coverage 
(fraction of CpGs with detectable intensity values above background) and bisulphite 
conversion efficiency (BSCE) using the controls provided on the Illumina Beadchip. Of the 
192 samples, one sample had failed BSCE and an additional four samples had relatively low 
coverage and BSCE. These samples were removed, leaving a total of 187 samples with 
approximately 81% global coverage (22,486 CpG sites). Intra-array normalisation was 
performed by the Illumina BeadStudio 3.2. software. The resulting β-valued data matrix was 
normalised further using a quantile-normalisation strategy, designed to reduce unwanted 
inter-array variation. The normalised and raw data are available from GEO (Gene Expression 
Omnibus, NCBI) under the accession number GSE20067. 
 
Singular Value Decomposition and Significance of Singular Values 
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Singular Value Decomposition (SVD) provides a linear representation of the data in 
terms of a relatively small number of components, which capture the most salient patterns 
of variation [36]. We verified that the first component of a SVD analysis on the β-valued 
data matrix captures over 90% of the variation in the data, representing the inherent bi-
modality of the methylation value distribution (see Figures 1a and 1b). Thus, to correctly 
evaluate the statistical significance of the remaining components of variation, the 
normalised data matrix needs to be adjusted by removing this background variation, by 
subtracting out the top principal component. This is essentially equivalent to normalising 
the data matrix by the mean profile. SVD was subsequently reapplied to the normalised 
adjusted data and the spectrum of singular values compared to the null distribution 
obtained by considering random matrices [37, 38]. Specifically, the normalised adjusted 
data was randomised by permuting the CpGs, using a distinct permutation for each sample. 
Subsequently, SVD was performed on the randomised data matrix and the fraction of 
variation of the inferred singular values compared to the fractions of variation of the 
unpermuted data (Figure 2). Using multiple randomisations we verified that the null 
distribution of singular values was very tight (Figure 2), as expected since null singular 
values reflect a global property of the randomised data, which should be robust to further 
randomisations of the data. Thus, significant components of variation were selected as 
those whose variation was larger than the expected variation under the null-hypothesis. 
This gave five principal components in addition to the top component, making a total of six. 
The biological significance of the five components of variation (top principal component did 
not correlate with any phenotype) was tested by correlation to phenotypes of interest and 
experimental factors (Figure 3). For continuous and ordinal variables (e.g. BSCE, age) 
associations were evaluated using linear regression, for categorical variables (e.g. Beadchip) 
we used a Kruskal-Wallis test. For the time to onset of nephropathy (CC-case/control) we 
used a Cox-regression with time to event = time to onset of nephropathy (NP), and event = 
1 (NP), 0 (no NP). 
 
Supervised analysis 10 
 
 
Association between CpG-valued methylation profiles and diabetic nephropathy was 
performed using a Cox-regression model where time to event equals the time between 
diagnosis of T1D to the onset of nephropathy. Multivariate regressions were performed for 
each CpG separately and included factors for chip, BSCE, sex, cohort and age at sample 
draw. To correct for multiple testing we estimated the false discovery rate (FDR) using the 
q-value framework [39]. We have shown previously that the analytical q-value estimates are 
similar to those obtained using permutations of sample labels preserving the potential 
correlative structure between CpGs [31]. 
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Results 
 
Methylation profile of arrays 
 
The methylation values as defined by β scores ranging between 1 and 0, or fully to 
non-methylated, are displayed for all 27,578 CpGs queried as histograms in Figures 1a and 
1b, for controls and cases respectively.  Both show a similar pattern with a high peak of 
hypomethylated loci and a low peak in the hypermethylated loci. This is the expected U 
shape of methylation pattern of the genome but due to the array design which is skewed 
towards promoter region CpGs in CGIs shows the reverse pattern with a larger peak at the 
low end of the distribution.  The minimum and maximum β values results for a 
representative chromosome, chromosome 1, are shown in Figure 4. This displays the 
individual results for the 2,903 probed CpGs that reside across this chromosome, for cases 
and controls separately. Scatter plots showed highly equivalent intensity scores (r
2 = 0.9990) 
and average β scores (r
2 = 0.9996) between cases and controls (data not shown).  
 
DNA methylation analysis 
 
SVD of the normalised data revealed significant components of variation that 
correlated with age, time to onset of nephropathy, sex, but also with experimental factors 
including chip, cohort and bisulphite conversion efficiency (Figures 2 and 3). As age and 
experimental factors could confound the analysis, we identified CpGs correlating with time 
to onset of nephropathy by applying a multivariate Cox-regression model to each CpG site, 
including the confounding factors as covariates. We observed that the resulting p-value 
distribution was significantly different from a uniform distribution with an excess of p-
values close to 0, suggesting that a significant number of CpGs are correlated with time to 
onset of nephropathy (Figure 5). This involves the contribution of directional methylation 
increases or decreases observed in cases, with respect to the period of time that 
nephropathy took to develop, and controls, whom had had a variable period of T1D without 12 
 
developing nephropathy. At an FDR = 0.15, we observed 263 CpGs as conferring increased 
risk and 162 CpGs conferring decreased risk for nephropathy, respectively (Additional File 2: 
Supplementary Table S1). However, whether these changes are related to cause or effect of 
early/late onset of nephropathy cannot be answered by this study. Gene set enrichment 
analysis searches for genes that share common biological function, chromosomal location, 
or regulation, and this analysis run on these data using the Molecular Signatures Database 
(MSigDB v2.5) [40] did not reveal any significant associations, after correction for multiple 
testing. Using a more stringent FDR of 0.05 resulted in a set of 19 CpGs and these are listed 
in Table 2.  The CpG cg07341907, located 5’ of the UNC13B gene, was the only CpG near a 
previously identified T1D nephropathy-associated candidate gene within this group. The box 
plot for adjusted methylation Z-score differences for this CpG is shown in Figure 6, with 
higher levels of methylation in the case group (0.00557) versus controls (-0.00563) 
(Uncorrected average β values were 0.147 and 0.157, for controls and cases respectively). 
The putative association SNP rs13293564 resides within the first intron of this gene [13]. 
MUNC13, the protein coded for by UNC13B, has been shown to be up-regulated in the renal 
cortex of rats with streptozotocin-induced diabetes and its expression is induced by 
hyperglycaemia [41]. 
To investigate whether there was a significant co-directional change of CpGs within 
1 kb of each other, the normalised results for each of those proximal pairs within this 
distance were combined and compared in a case versus control analysis, with two of the 
genes in Table 2, PPAPR3 (cg02590345 and cg16898420 – separated by 119 bp) and TRPS1 
(cg12569516 and cg21312090 – separated by 534 bp) also being in the top ten results of 
this analysis (data not shown).  
 
Discussion 
 
This study investigated the methylation state of approximately 14,000 CGIs in 
promoter regions of genes spread throughout the genome in a cohort of 192 type 1 diabetic 
patients, half of whom had developed diabetic nephropathy. A Cox-regression model was 13 
 
utilised whereby the effect of a genetic susceptibility has a multiplicative effect over time 
on the risk of a subject developing nephropathy. This analysis, after accounting for 
confounding effects, identified an excess of CpG sites which were observed to have a 
change in methylation status that could be correlated with duration of diabetes prior to 
onset of nephropathy with a FDR of 0.15. Of these observations 263 CpGs were identified as 
conferring increased risk and 162 CpGs conferring decreased risk for nephropathy, 
respectively and co-localised to 421 unique genic regions. However this dataset did not 
reveal any significant enrichment of particular physiological gene set pathways.  
Using a more stringent FDR cut-off of 0.05, a set of 19 CpGs was identified (in 19 
unique gene CGIs). One CpG in this list, cg07341907 is located 18 bp upstream of the 
transcription start site of a previously identified type 1 diabetic nephropathy gene, UNC13B 
[13]. Levels of methylation for this CpG were shown to be slightly higher in the case group 
compared with controls. Whilst expression of this gene has been shown to be increased in 
models of nephropathy and hyperglycaemia [41] the expression effect of methylation 
changes can often be difficult to predict [42]. The other CpG assayed within this genic 
region, cg02096633, is located ~0.5 kb further downstream, 197 bp into the first intron and 
shows consistently low methylation levels in both cases and controls (β-value averages 
0.051 and 0.052 respectively).  The susceptibility SNP, rs13293564 resides within the first 
intron and in Caucasians (from CEU HapMap data) is within a linkage disequilibrium block of 
23 kb that includes the CGI. Tregouet et al. could determine no plausible function for the 
intronic SNP, however did identify five SNPs in strong linkage disequilibrium with this SNP 
that reside within the plausible promoter region [13]. Two of which (rs10081672 and 
rs10972333) were found to affect potential transcription factor binding sites. Additionally, 
the former SNP (rs10081672) creates or abrogates a CpG site depending on which allele is 
present. Therefore, modification of the promoter region of this gene whether genetically or 
epigenetically or in combination could influence its expression by affecting transcription 
factor binding. Tregouet et al. proposed that UNC13B mediates apoptosis in glomerular cells 
due to hyperglycemia, and they therefore suggested that this association could indicate 
initiation of nephropathy [13].  14 
 
Whilst the 27K Infinium assay enables high-throughput investigation of individual 
CpG sites with high resolution, and is a considerable improvement on the previous Golden-
Gate methylation assay, this methodology still has some limitations. Only approximately 
0.1% of the total number of CpGs within the genome are assessed, however the placement 
of these CpGs are predominately within the CpG Islands with high likelihood of critical 
effects on promoter activity. As these CpGs can significantly affect or silence expression, 
changes can be more deleterious than gene sequence variants, therefore increasing the 
potential power of the assay. Additionally not all CpG sites need to be assessed as 
correlation of CpG status between sites can extend up to 1kb [43]. Whist dramatic switching 
on or off facilitated by DNA methylation may occur within these promoter regions, more 
subtle and perhaps dynamic effects may however be missed that are occurring in the 
surrounding CGI shores (regions within 2 kb of the islands) [44]. Changes in gene body 
methylation that may influence the expression of certain isoforms, by effecting the inclusion 
or exclusion of certain exons, are also not assayed.  Additionally this array does have a bias 
towards cancer and imprinted genes; with ~200 of these having 3-20 CpG probes per 
promoter. Increasing knowledge with regards to the most biologically informative CpG sites 
and future up scaling will undoubtedly improve targeted platforms, although a more in 
depth investigation of all of the CpGs of the genome would require a differing approach. An 
enrichment technique such as MeDIP-Seq would gain a representative genome wide picture 
but this lacks the base pair resolution of this array [45]. Isolated studies utilising full 
bisulphite sequencing of a very small number of genomes have recently been published 
[26], however scaling up to large numbers of cases and controls currently remains 
prohibitive due to cost. 
Like all genome-wide association studies this study was designed to find statistically 
significant associations, in this case with DNA methylation variation not with genotype, but 
not to identify the underlying mechanism(s) for the cause or function of the observed 
variation. Although DNA methylation is tissue-specific, examination of peripheral whole 
blood was informative in this case in order to determine whether any genome-wide 
methylation signal changes could be detected in this easily accessible surrogate tissue. 15 
 
Whilst only a small number of significant sites were identified, due to the stringent False 
Discovery Rate cut-off implemented, this experiment did identify possible biomarkers in this 
pathogenic process with more easily implementable clinical utility potential. Therefore, this 
indicates that active disease processes can be identified in the DNA methylation pattern of 
peripheral blood and be a possible marker of these [31]. The development, as well as the 
progression, of diabetic nephropathy has been linked to the same inflammatory cell 
changes that are implicated in the progression of T1D itself, such as the activated T cells 
involved in the destruction of islet β cells [7]. Furthermore, additional inflammatory-related 
or other signals may be present in peripheral blood DNA that require isolation of specific 
cell types to detect and other methylation change signals may only be able to be identified 
in the affected renal cells themselves. 
 
Conclusion 
 
This study is one of the first to investigate a complex disease trait utilising this high-
throughput DNA methylation 27K array based assay. The effect of length of T1D status 
before developing or not developing nephropathy was observed to show a correlation with 
respect to methylation scores of individual CpG loci. By the examination of a cohort of 192 
T1D patients this study has confirmed the utility of this approach to genome wide DNA 
methylation analysis and the potential prospects for larger and subsequent replication 
studies of epigenomic factors in common diseases.   
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Table 1: Subjects 
 
  Controls  Cases 
Number  96  96 
Age  43.2  42.8 
Sex (M/F)  47/49  48/48 
Age at Diagnosis  16.3  16.2 
Duration T1D  27.8  27.5 
 
Subjects: Number, Average Age, Sex proportion (Male/Female), Duration of T1D 18 
 
Table 2: Methylation Associations  
 
Ilmn CpG ID  Gene  Gene Function  Location  coef  exp(coef)  se(coef)  z  Pr(>|z|)  Q value 
cg01172656  NRBF2 
Transcription 
regulation  10:64563126  0.631  1.880  0.136  4.653  3.266 x 10
-06  0.031 
cg18346038  PIGU 
GPI-anchor 
biosynthesis 
20:32728489  0.624  1.867  0.136  4.603  4.164 x 10
-06  0.031 
cg00117172  RUNX3 
Transcription 
regulation  1:25128425  0.682  1.977  0.150  4.548  5.427 x 10
-06  0.031 
cg02068676  COBRA1 
Negative 
regulation of 
transcription 
9:139269304  0.662  1.938  0.149  4.447  8.703 x 10
-06  0.037 
cg00025138  MAP3K9 
Mixed-lineage 
kinase 
14:70345670  0.543  1.721  0.125  4.335  1.457 x 10
-05  0.046 
cg03221776  MFSD3 
Transmembrane 
transport  8:145704779  0.520  1.682  0.121  4.308  1.644 x 10
-05  0.046 
cg12181621  HIST1H3I 
Nucleosome 
assembly 
6:27948047  0.558  1.748  0.132  4.216  2.486 x 10
-05  0.048 
cg03752885  DAPK3 
Induction of 
apoptosis  19:3920736  0.492  1.636  0.118  4.189  2.798 x 10
-05  0.048 
cg12688215  KTI12  ATP binding  1:52271816  0.446  1.563  0.107  4.175  2.976 x 10
-05  0.048 
cg07341907  UNC13B  Exocytosis  9:35151971  0.606  1.833  0.145  4.169  3.056 x 10
-05  0.048 
cg26850145  ZBTB5 
Transcription 
regulation  9:37455023  -0.485  0.616  0.117  -4.142  3.441 x 10
-05  0.048 
cg21312090  TRPS1 
NLS-bearing 
substrate import 
into nucleus 
8:116750901  0.441  1.555  0.107  4.135  3.543 x 10
-05  0.048 
cg23266266  DCUN1D4  -  4:52403466  0.560  1.751  0.136  4.117  3.847 x 10
-05  0.048 
cg04466870  SFXN4 
Transmembrane 
transport 
10:12091517
0 
0.477  1.611  0.116  4.102  4.092 x 10
-05  0.048 19 
 
cg16898420  PPAPR3  Catalytic activity  9:102830899  -0.711  0.491  0.175  -4.066  4.786 x 10
-05  0.048 
cg17260725  CCNB2  Cell division  15:57184580  0.523  1.687  0.129  4.0596  4.915 x 10
-05  0.048 
cg17428423  DOC2A 
Regulation of 
calcium ion-
dependent 
exocytosis 
16:29929633  -0.728  0.483  0.180  -4.053  5.049 x 10
-05  0.048 
cg18731014  ZNF639 
Transcription 
regulation  3:180524284  0.556  1.744  0.137  4.050  5.122 x 10
-05  0.048 
cg21830413  VPS26 
Protein 
transport 
10:70554257  0.472  1.604  0.117  4.036  5.430 x 10
-05  0.048 
 
Cox-Regression analysis results of CpGs, with FDR (q value) <0.05, for time to develop 
nephropathy. (Location given as Chromosome:Base Pair (Build Hs 36.1)) 
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Figure Legends 
Figure 1 – Average β values. 
Figure 1a (top): Controls, Figure 1b (bottom): Cases - Average β values across array. 
 
Figure 2 – Fraction of variation associated with principal components. 
Fraction of variation associated with principal components after adjustment for the top 
component which captures the inherent bi-modality of the methylation distribution. Red 
denotes the observed values, black denotes those obtained by randomly scrambling up the 
data matrix. Each black dot represents the value of 10 distinct randomisations, which all 
yield the same value as singular values represent measures of global variation which 
themselves are invariant under a global randomisation of the data.  
 
Figure 3 – Correlation of principle components to phenotype/experimental factors. 
Correlation of principal components (top component removed as it did not correlate with 
any phenotype) to phenotypes of interest and experimental factors: BS conversion 
(bisulphite conversion, C1(green), C2(blue)), Sex, Cohort, Chip, Batch, Age at Draw (Age 
when sample taken), Duration T1D, Age at Diagnosis, CC (time to onset of NP) 
Colour key: dark red = p value <10-10, red = p value <10-5, orange = p value < 10-2, pink = p 
value < 0.05, white = p value > 0.05. 
 
Figure 4: Maximum and minimum β values for Chromosome 1. 
Maximum and minimum β values across the 2903 probed CpGs located on Chromosome 1 
for Controls and Cases. 
   
Figure 5 – Nephropathy and duration type 1 diabetes p values.  
Histogram of p-values after explicit correction for all potentially confounding factors reveals 
an excess of significant p values for CpGs correlated with Nephropathy and duration of Type 
1 Diabetes.  
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Figure 6 – Z score values for cg07341907.  
Box plot for adjusted comparison of methylation Z-score values for the UNC13B promoter 
CpG:cg07341907 on controls (0) and cases (1). 
 
Additional File 1 
Supplementary Figure S1 
Distribution of CpG sites on Infinium platform. 
(Top, Left) Chromosome Distribution of CpG sites. (Top, Right) Distance to Transcription 
Start Site of CpG Locus. (Bottom, Left) Interrogated CpG Islands: near genes, near miRNA. 
(Bottom, Right) Number of CpG sites per CpG Island. 
 
Additional File 2 
Supplementary Table S1. 
List of CpGs with q value < 0.15. 
Column headings are IlmnID  = Illumina CpG ID, Gene_ID = Entrez Gene ID, Symbol = Gene 
Symbol, coef = coefficient, exp(coef) = exponential of coefficient, se(coef) = standard error 
of coefficient, z = z score, Pr(>|z|) = probability greater than absolute z score, q value 
 
   
 
References 
 
1.  Ansell D, Feehally J, Fogarty D, Tomsom CRV, Williams AJ, Warwick G: UK Renal Registry 
Annual Report. 2009/06/30 edn. Bistol; 2008. 
2.  U.S. Renal Data System: US Renal Data System 2008 Annual Data Report. In Atlas of 
Chronic Kidney Disease and End Stage Renal Disease in the United States (National Institutes 
of Health NIoDaDaKD ed. Bethesda, MD. : National Institutes of Health, National Institutes 
of Diabetes and Digestive and Kidney Diseases 2008. 
3.  Ibrahim HN, Hostetter TH: Diabetic nephropathy. J Am Soc Nephrol 1997, 8:487-493. 
4.  O'Connor AS, Schelling JR: Diabetes and the kidney. Am J Kidney Dis 2005, 46:766-773. 
5.  Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. 
Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161-
1165. 22 
 
6.  Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the 
development of diabetic nephropathy in patients with IDDM. Diabetologia 1996, 39:940-
945. 
7.  Ichinose K, Kawasaki E, Eguchi K: Recent advancement of understanding pathogenesis of 
type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007, 
27:554-564. 
8.  Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Haring HU, Schleicher ED: AP-1 proteins mediate 
hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J 
Am Soc Nephrol 2000, 11:2007-2016. 
9.  Katavetin P, Miyata T, Inagi R, Tanaka T, Sassa R, Ingelfinger JR, Fujita T, Nangaku M: High 
glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative 
stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc 
Nephrol 2006, 17:1405-1413. 
10.  Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic 
nephropathy. J Am Soc Nephrol 2008, 19:433-442. 
11.  He B, Osterholm AM, Hoverfalt A, Forsblom C, Hjorleifsdottir EE, Nilsson AS, Parkkonen M, 
Pitkaniemi J, Hreidarsson A, Sarti C, et al: Association of genetic variants at 3q22 with 
nephropathy in patients with type 1 diabetes mellitus. Am J Hum Genet 2009, 84:5-13. 
12.  Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, Wanic K, Moczulski D, 
Canani L, Araki S, et al: High-density single nucleotide polymorphism genome-wide linkage 
scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant 
sibpair approach. Diabetes 2008, 57:2519-2526. 
13.  Tregouet DA, Groop PH, McGinn S, Forsblom C, Hadjadj S, Marre M, Parving HH, Tarnow L, 
Telgmann R, Godefroy T, et al: G/T substitution in intron 1 of the UNC13B gene is 
associated with increased risk of nephropathy in patients with type 1 diabetes. Diabetes 
2008, 57:2843-2850. 
14.  Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, 
Arends VL, et al: Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants 
are associated with the development and progression of diabetic nephropathy: the 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Genetics study. Diabetes 2008, 57:218-228. 
15.  Leak TS, Perlegas PS, Smith SG, Keene KL, Hicks PJ, Langefeld CD, Mychaleckyj JC, Rich SS, 
Kirk JK, Freedman BI, et al: Variants in intron 13 of the ELMO1 gene are associated with 
diabetic nephropathy in African Americans. Ann Hum Genet 2009, 73:152-159. 
16.  Pezzolesi MG, Katavetin P, Kure M, Poznik GD, Skupien J, Mychaleckyj JC, Rich SS, Warram 
JH, Krolewski AS: confirmation of genetic associations at ELMO1 in the GoKinD collection 
supports its role as a susceptibility gene in diabetic nephropathy. Diabetes 2009, 58:2698-
2702. 
17.  Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, 
Canani LH, Bochenski J, et al: Genome-wide association scan for diabetic nephropathy 
susceptibility genes in type 1 diabetes. Diabetes 2009, 58:1403-1410. 
18.  Richards EJ: Inherited epigenetic variation--revisiting soft inheritance. Nat Rev Genet 2006, 
7:395-401. 23 
 
19.  Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga S: 
Altered gene expression related to glomerulogenesis and podocyte structure in early 
diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006, 
55:2747-2756. 
20.  Krause B, Sobrevia L, Casanello P: Epigenetics: new concepts of old phenomena in vascular 
physiology. Curr Vasc Pharmacol 2009, 7:513-520. 
21.  Turunen MP, Aavik E, Yla-Herttuala S: Epigenetics and atherosclerosis. Biochim Biophys 
Acta 2009, 1790:886-891. 
22.  Ingrosso D, Perna AF: Epigenetics in hyperhomocysteinemic states. A special focus on 
uremia. Biochim Biophys Acta 2009, 1790:892-899. 
23.  Ekstrom TJ, Stenvinkel P: The epigenetic conductor: a genomic orchestrator in chronic 
kidney disease complications? J Nephrol 2009, 22:442-449. 
24.  Lund G, Zaina S: Atherosclerosis risk factors can impose aberrant DNA methylation 
patterns: a tale of traffic and homocysteine. Curr Opin Lipidol 2009, 20:448-449. 
25.  Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R: Non-CpG methylation is 
prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. 
Proc Natl Acad Sci U S A 2000, 97:5237-5242. 
26.  Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, 
Ngo QM, et al: Human DNA methylomes at base resolution show widespread epigenomic 
differences. Nature 2009, 462:315-322. 
27.  Beck S, Rakyan VK: The methylome: approaches for global DNA methylation profiling. 
Trends Genet 2008, 24:231-237. 
28.  Saxonov S, Berg P, Brutlag DL: A genome-wide analysis of CpG dinucleotides in the human 
genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 2006, 
103:1412-1417. 
29.  Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson K: Genome-wide 
DNA methylation profiling using Infinium assay. Epigenomics 2009, 1:177-200. 
30.  Bibikova M, Fan JB: GoldenGate assay for DNA methylation profiling. Methods Mol Biol 
2009, 507:149-163. 
31.  Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones 
A, Lechner M, Beck S, Jacobs IJ, Widschwendter M: An epigenetic signature in peripheral 
blood predicts active ovarian cancer. PLoS One 2009, 4:e8274. 
32.  Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, 
Sigurdsson A, Baker A, Palsson A, Masson G, et al: A common variant on chromosome 9p21 
affects the risk of myocardial infarction. Science 2007, 316:1491-1493. 
33.  Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, 
Hadjadj S, et al: A genome-wide association study identifies novel risk loci for type 2 
diabetes. Nature 2007, 445:881-885. 
34.  Ihaka R, Gentleman R: R: A Language for Data Analysis and Graphics. Journal of 
Computational and Graphical Statistics 1996, Vol 5:299-314. 
35.  Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, 
Gentry J, et al: Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol 2004, 5:R80. 24 
 
36.  Hastie T, Tibshirani R, Friedman JH: The elements of statistical learning : data mining, 
inference, and prediction : with 200 full-color illustrations. New York: Springer; 2001. 
37.  Leek JT, Storey JD: Capturing heterogeneity in gene expression studies by surrogate 
variable analysis. PLoS Genet 2007, 3:1724-1735. 
38.  Buja A, Eyuboglu N: Remarks on Parallel Analysis. Multivariate Behavioral Research 1992, 
27:509-540. 
39.  Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci 
U S A 2003, 100:9440-9445. 
40.  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, 
Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 
2005, 102:15545-15550. 
41.  Goldenberg NM, Silverman M: Rab34 and its effector munc13-2 constitute a new pathway 
modulating protein secretion in the cellular response to hyperglycemia. Am J Physiol Cell 
Physiol 2009, 297:C1053-1058. 
42.  Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. 
Nat Rev Genet 2008, 9:465-476. 
43.  Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, Burton J, Cox TV, Davies R, 
Down TA, et al: DNA methylation profiling of human chromosomes 6, 20 and 22. Nat 
Genet 2006, 38:1378-1385. 
44.  Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione 
M, Webster M, et al: The human colon cancer methylome shows similar hypo- and 
hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 41:178-
186. 
45.  Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Graf S, Johnson N, Herrero J, 
Tomazou EM, et al: A Bayesian deconvolution strategy for immunoprecipitation-based 
DNA methylome analysis. Nat Biotechnol 2008, 26:779-785. 
 
 Figure 1Figure 4Figure 6Additional files provided with this submission:
Additional file 1: Supplementary-Figure-S1.png, 130K
http://www.biomedcentral.com/imedia/4854591274308819/supp1.png
Additional file 2: Supplementary_table_S1.xls, 106K
http://www.biomedcentral.com/imedia/5302899444308821/supp2.xls